sampleID;AJCC_Stage_nature2012;Age_at_Initial_Pathologic_Diagnosis_nature2012;CN_Clusters_nature2012;Converted_Stage_nature2012;Days_to_Date_of_Last_Contact_nature2012;Days_to_date_of_Death_nature2012;ER_Status_nature2012;Gender_nature2012;HER2_Final_Status_nature2012;Integrated_Clusters_no_exp__nature2012;Integrated_Clusters_unsup_exp__nature2012;Integrated_Clusters_with_PAM50__nature2012;Metastasis_Coded_nature2012;Metastasis_nature2012;Node_Coded_nature2012;Node_nature2012;OS_Time_nature2012;OS_event_nature2012;PAM50Call_RNAseq;PAM50_mRNA_nature2012;PR_Status_nature2012;RPPA_Clusters_nature2012;SigClust_Intrinsic_mRNA_nature2012;SigClust_Unsupervised_mRNA_nature2012;Survival_Data_Form_nature2012;Tumor_T1_Coded_nature2012;Tumor_nature2012;Vital_Status_nature2012;_INTEGRATION;_PANCAN_CNA_PANCAN_K8;_PANCAN_Cluster_Cluster_PANCAN;_PANCAN_DNAMethyl_BRCA;_PANCAN_DNAMethyl_PANCAN;_PANCAN_RPPA_PANCAN_K8;_PANCAN_UNC_RNAseq_PANCAN_K16;_PANCAN_miRNA_PANCAN;_PANCAN_mirna_BRCA;_PANCAN_mutation_PANCAN;_PATIENT;_cohort;_primary_disease;_primary_site;additional_pharmaceutical_therapy;additional_radiation_therapy;additional_surgery_locoregional_procedure;additional_surgery_metastatic_procedure;age_at_initial_pathologic_diagnosis;anatomic_neoplasm_subdivision;axillary_lymph_node_stage_method_type;axillary_lymph_node_stage_other_method_descriptive_text;bcr_followup_barcode;bcr_patient_barcode;bcr_sample_barcode;breast_cancer_surgery_margin_status;breast_carcinoma_estrogen_receptor_status;breast_carcinoma_immunohistochemistry_er_pos_finding_scale;breast_carcinoma_immunohistochemistry_pos_cell_score;breast_carcinoma_immunohistochemistry_prgstrn_rcptr_ps_fndng_scl;breast_carcinoma_primary_surgical_procedure_name;breast_carcinoma_progesterone_receptor_status;breast_carcinoma_surgical_procedure_name;breast_neoplasm_other_surgical_procedure_descriptive_text;cytokeratin_immunohistochemistry_staining_method_mcrmtstss_ndctr;days_to_additional_surgery_locoregional_procedure;days_to_additional_surgery_metastatic_procedure;days_to_birth;days_to_collection;days_to_death;days_to_initial_pathologic_diagnosis;days_to_last_followup;days_to_last_known_alive;days_to_new_tumor_event_additional_surgery_procedure;days_to_new_tumor_event_after_initial_treatment;disease_code;distant_metastasis_present_ind2;er_detection_method_text;er_level_cell_percentage_category;fluorescence_in_st_hybrdztn_dgnstc_prcdr_chrmsm_17_sgnl_rslt_rng;followup_case_report_form_submission_reason;form_completion_date;gender;her2_and_centromere_17_positive_finding_other_measuremnt_scl_txt;her2_erbb_method_calculation_method_text;her2_erbb_pos_finding_cell_percent_category;her2_erbb_pos_finding_fluorescence_n_st_hybrdztn_clcltn_mthd_txt;her2_immunohistochemistry_level_result;her2_neu_and_centromere_17_copy_number_analysis_npt_ttl_nmbr_cnt;her2_neu_breast_carcinoma_copy_analysis_input_total_number;her2_neu_chromosone_17_signal_ratio_value;her2_neu_metastatic_breast_carcinoma_copy_analysis_inpt_ttl_nmbr;histological_type;histological_type_other;history_of_neoadjuvant_treatment;hr2_n_nd_cntrmr_17_cpy_nmbr_mtsttc_brst_crcnm_nlyss_npt_ttl_nmbr;icd_10;icd_o_3_histology;icd_o_3_site;immunohistochemistry_positive_cell_score;informed_consent_verified;init_pathology_dx_method_other;initial_pathologic_diagnosis_method;initial_weight;is_ffpe;lab_proc_her2_neu_immunohistochemistry_receptor_status;lab_procedure_her2_neu_in_situ_hybrid_outcome_type;lost_follow_up;lymph_node_examined_count;margin_status;menopause_status;metastatic_breast_carcinm_ps_fndng_prgstrn_rcptr_thr_msr_scl_txt;metastatic_breast_carcinom_lb_prc_hr2_n_mmnhstchmstry_rcptr_stts;metastatic_breast_carcinoma_erbb2_immunohistochemistry_levl_rslt;metastatic_breast_carcinoma_estrogen_receptor_detection_mthd_txt;metastatic_breast_carcinoma_estrogen_receptor_status;metastatic_breast_carcinoma_estrogen_receptr_lvl_cll_prcnt_ctgry;metastatic_breast_carcinoma_her2_erbb_method_calculatin_mthd_txt;metastatic_breast_carcinoma_her2_erbb_pos_findng_cll_prcnt_ctgry;metastatic_breast_carcinoma_her2_neu_chromosone_17_signal_rat_vl;metastatic_breast_carcinoma_immunhstchmstry_r_pstv_fndng_scl_typ;metastatic_breast_carcinoma_immunohistochemistry_er_pos_cell_scr;metastatic_breast_carcinoma_immunohistochemistry_pr_pos_cell_scr;metastatic_breast_carcinoma_lab_proc_hr2_n_n_st_hybrdztn_tcm_typ;metastatic_breast_carcinoma_pos_finding_hr2_rbb2_thr_msr_scl_txt;metastatic_breast_carcinoma_progestern_rcptr_lvl_cll_prcnt_ctgry;metastatic_breast_carcinoma_progesterone_receptor_dtctn_mthd_txt;metastatic_breast_carcinoma_progesterone_receptor_status;metastatic_site_at_diagnosis;metastatic_site_at_diagnosis_other;methylation_Clusters_nature2012;miRNA_Clusters_nature2012;mtsttc_brst_crcnm_flrscnc_n_st_hybrdztn_dgnstc_prc_cntrmr_17_sgn;mtsttc_brst_crcnm_hr2_rbb_ps_fndng_flrscnc_n_st_hybrdztn_clcltn;mtsttc_brst_crcnm_mmnhstchmstry_prgstrn_rcptr_pstv_fndng_scl_typ;new_neoplasm_event_occurrence_anatomic_site;new_neoplasm_event_type;new_neoplasm_occurrence_anatomic_site_text;new_tumor_event_additional_surgery_procedure;new_tumor_event_after_initial_treatment;number_of_lymphnodes_positive_by_he;number_of_lymphnodes_positive_by_ihc;oct_embedded;other_dx;pathologic_M;pathologic_N;pathologic_T;pathologic_stage;pathology_report_file_name;patient_id;person_neoplasm_cancer_status;pgr_detection_method_text;pos_finding_her2_erbb2_other_measurement_scale_text;pos_finding_metastatic_brst_crcnm_strgn_rcptr_thr_msrmnt_scl_txt;pos_finding_progesterone_receptor_other_measurement_scale_text;positive_finding_estrogen_receptor_other_measurement_scale_text;postoperative_rx_tx;primary_lymph_node_presentation_assessment;progesterone_receptor_level_cell_percent_category;project_code;radiation_therapy;sample_type;sample_type_id;surgical_procedure_purpose_other_text;system_version;targeted_molecular_therapy;tissue_prospective_collection_indicator;tissue_retrospective_collection_indicator;tissue_source_site;tumor_tissue_site;vial_number;vital_status;year_of_initial_pathologic_diagnosis;_GENOMIC_ID_TCGA_BRCA_exp_HiSeqV2_exon;_GENOMIC_ID_TCGA_BRCA_exp_HiSeqV2_PANCAN;_GENOMIC_ID_TCGA_BRCA_RPPA_RBN;_GENOMIC_ID_TCGA_BRCA_mutation;_GENOMIC_ID_TCGA_BRCA_PDMRNAseq;_GENOMIC_ID_TCGA_BRCA_hMethyl450;_GENOMIC_ID_TCGA_BRCA_RPPA;_GENOMIC_ID_TCGA_BRCA_PDMRNAseqCNV;_GENOMIC_ID_TCGA_BRCA_mutation_curated_wustl_gene;_GENOMIC_ID_TCGA_BRCA_hMethyl27;_GENOMIC_ID_TCGA_BRCA_PDMarrayCNV;_GENOMIC_ID_TCGA_BRCA_miRNA_HiSeq;_GENOMIC_ID_TCGA_BRCA_mutation_wustl_gene;_GENOMIC_ID_TCGA_BRCA_miRNA_GA;_GENOMIC_ID_TCGA_BRCA_exp_HiSeqV2_percentile;_GENOMIC_ID_data/public/TCGA/BRCA/miRNA_GA_gene;_GENOMIC_ID_TCGA_BRCA_gistic2thd;_GENOMIC_ID_data/public/TCGA/BRCA/miRNA_HiSeq_gene;_GENOMIC_ID_TCGA_BRCA_G4502A_07_3;_GENOMIC_ID_TCGA_BRCA_exp_HiSeqV2;_GENOMIC_ID_TCGA_BRCA_gistic2;_GENOMIC_ID_TCGA_BRCA_PDMarray;
TCGA-A1-A0SM-01;Stage IIA;77;2;Stage IIA;242;;Positive;MALE;Positive;;;;Negative;M0;Negative;N0;242;0;LumA;Luminal B;Negative;;-1;-3;enrollment;T_Other;T2;LIVING;TCGA-A1-A0SM-01;BRCA-LUAD+;C3-BRCA/Luminal;cluster 4;BRCA CIMP c7;;BRCA nonbasal-like c7;miRNA cluster 4;cluster 4;mutation c1uster 9;TCGA-A1-A0SM;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;77;Left;Sentinel lymph node biopsy plus axillary dissection;;;TCGA-A1-A0SM;;;Positive;;;;;Negative;Modified Radical Mastectomy;;;;;-28198;;;0;242;;;;;;;20-29%;2;;2010-12-6;MALE;;;;;3+;;21;11;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;Core needle biopsy;;;Positive;Positive;;3;Negative;;;;;;;;;;;;;;;;;;;;;4;4;;;;;;;;;0;;;No;M0;N0 (i-);T2;Stage IIA;;A0SM;TUMOR FREE;;;;;;;;;;;Primary Tumor;1;;6th;;NO;YES;A1;Breast;;LIVING;2007;e637db43-508a-4a37-92e4-eea96b35b65b;e637db43-508a-4a37-92e4-eea96b35b65b;;TCGA-A1-A0SM-01A-11D-A099-09;TCGA-A1-A0SM-01;TCGA-A1-A0SM-01A-11D-A10P-05;;TCGA-A1-A0SM-01;TCGA-A1-A0SM-01A-11D-A099-09;;TCGA-A1-A0SM-01;;TCGA-A1-A0SM-01A-11D-A099-09;TCGA-A1-A0SM-01;e637db43-508a-4a37-92e4-eea96b35b65b;TCGA-A1-A0SM-01;TCGA-A1-A0SM-01A-11D-A087-01;;TCGA-A1-A0SM-01A-11R-A084-07;e637db43-508a-4a37-92e4-eea96b35b65b;TCGA-A1-A0SM-01A-11D-A087-01;TCGA-A1-A0SM-01
TCGA-A8-A085-01;Stage IIB;44;5;Stage IIB;1124;;Positive;MALE;Negative;1;3;4;Negative;M0;Positive;N1;1124;0;LumB;Luminal B;Positive;LumA/B;-10;-3;enrollment;T_Other;T2;LIVING;TCGA-A8-A085-01;High;C3-BRCA/Luminal;cluster 4;BRCA CIMP c7;BRCA nonbasal-like c8;BRCA nonbasal-like c7;miRNA cluster 14;cluster 2;mutation c1uster 9;TCGA-A8-A085;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;44;Left;;;TCGA-A8-A085-F40839;TCGA-A8-A085;TCGA-A8-A085-01A;;Positive;;;;;Positive;Other;;;;;-16377;788;;0;1124;;;;;;;;;;2013-3-2;MALE;;;;;1+;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;;130;NO;Negative;Negative;NO;;Negative;;;;;;;;;;;;;;;;;;;;;4;2;;;;;;;;NO;;;False;No;M0;N1a;T2;Stage IIB;TCGA-A8-A085.64F84FF4-A477-4E1E-B4BB-E5614517229E.pdf;A085;TUMOR FREE;;;;;;YES;;;;NO;Primary Tumor;1;Surgical Resection;6th;;NO;YES;A8;Breast;A;LIVING;2008;4be8001c-c6a2-420c-8761-93469a6a7904;4be8001c-c6a2-420c-8761-93469a6a7904;TCGA-A8-A085-01A-21-A13B-20;TCGA-A8-A085-01A-11W-A019-09;TCGA-A8-A085-01;;96e8bae5-7cde-475e-b1ba-ec2ac2efeb6e;TCGA-A8-A085-01;TCGA-A8-A085-01A-11W-A019-09;TCGA-A8-A085-01A-11D-A00Y-05;TCGA-A8-A085-01;;TCGA-A8-A085-01A-11W-A019-09;TCGA-A8-A085-01;4be8001c-c6a2-420c-8761-93469a6a7904;TCGA-A8-A085-01;TCGA-A8-A085-01A-11D-A011-01;;TCGA-A8-A085-01A-11R-A00Z-07;4be8001c-c6a2-420c-8761-93469a6a7904;TCGA-A8-A085-01A-11D-A011-01;TCGA-A8-A085-01
TCGA-AC-A62V-01;;;;;;;;;;;;;;;;;;;;;;;;;;;;;TCGA-AC-A62V-01;;;;;;;;;;TCGA-AC-A62V;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;58;Right Lower Outer Quadrant;Axillary lymph node dissection alone;;TCGA-AC-A62V-F60177;TCGA-AC-A62V;TCGA-AC-A62V-01A;;Positive;;;;;Positive;Modified Radical Mastectomy;;NO;;;-21389;38;348;0;2;;;;;;;90-99%;;;2014-5-31;MALE;;;;;;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;Core needle biopsy;120;NO;;;NO;17;Negative;;;;;;;;;;;;;;;;;;;Bone;;;;;;;;;;;NO;3;;False;No;M1;N1a;T2;Stage IV;TCGA-AC-A62V.BBA96852-E70C-4D37-A185-611F568BE90C.pdf;A62V;WITH TUMOR;;;;;;YES;YES;<10%;;YES;Primary Tumor;1;;7th;;YES;NO;AC;Breast;A;DECEASED;2013;7a356940-c460-4714-a949-42afe6ea5d86;7a356940-c460-4714-a949-42afe6ea5d86;;;TCGA-AC-A62V-01;TCGA-AC-A62V-01A-11D-A31V-05;;TCGA-AC-A62V-01;;;;TCGA-AC-A62V-01;;;7a356940-c460-4714-a949-42afe6ea5d86;;TCGA-AC-A62V-01A-11D-A31T-01;TCGA-AC-A62V-01;;7a356940-c460-4714-a949-42afe6ea5d86;TCGA-AC-A62V-01A-11D-A31T-01;
TCGA-AN-A0FE-01;;;;;;;;;;;;;;;;;;;;;;;;;;;;;TCGA-AN-A0FE-01;;;;;;;;;;TCGA-AN-A0FE;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;;;;;;;TCGA-AN-A0FE-01A;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;330;NO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;False;;;;;;;;;;;;;;;;;;;Primary Tumor;1;;;;;;;;A;;;;;;;;;;;;TCGA-AN-A0FE-01A-11D-A00Y-05;;;;;;;;;TCGA-AN-A0FE-01A-11R-A00Z-07;;;
TCGA-AN-A0FG-01;;;;;;;;;;;;;;;;;;;;;;;;;;;;;TCGA-AN-A0FG-01;;;;;;;;;;TCGA-AN-A0FG;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;;;;;;;TCGA-AN-A0FG-01A;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;400;NO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;False;;;;;;;;;;;;;;;;;;;Primary Tumor;1;;;;;;;;A;;;;;;;;;;;;TCGA-AN-A0FG-01A-11D-A00Y-05;;;;;;;;;TCGA-AN-A0FG-01A-11R-A00Z-07;;;
TCGA-AO-A1KQ-01;Stage IIIB;84;4;Stage IIIB;1519;;Positive;MALE;Negative;;;;Negative;M0;Positive;N1;1519;0;LumB;;Positive;;;;followup;T_Other;T4;LIVING;TCGA-AO-A1KQ-01;High;C3-BRCA/Luminal;cluster 2;BRCA non-CIMP c9;BRCA nonbasal-like c8;BRCA nonbasal-like c7;miRNA cluster 4;cluster 4;;TCGA-AO-A1KQ;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;84;Left Upper Inner Quadrant|Left Upper Outer Quadrant|Left Lower Inner Quadrant|Left;Sentinel lymph node biopsy plus axillary dissection;;TCGA-AO-A1KQ-F21775;TCGA-AO-A1KQ;TCGA-AO-A1KQ-01A;;Positive;4 Point Scale;3+;4 Point Scale;;Positive;Modified Radical Mastectomy;;NO;;;-30859;1553;;0;1882;;;;;NO;;90-99%;;Scheduled Follow-up Submission;2012-2-20;MALE;;;<10%;;1+;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;4+;YES;;Core needle biopsy;540;NO;Negative;;;9;Negative;;;;;;;;;;;;;;;;;;;;;2;4;;;;;;;;NO;2;0;True;No;M0;N1;T4;Stage IIIB;TCGA-AO-A1KQ.EB5199BA-6164-4CFB-AFAA-B41544B83103.pdf;A1KQ;TUMOR FREE;;;;;;;YES;80-89%;;NO;Primary Tumor;1;;6th;YES;NO;YES;AO;Breast;A;LIVING;2006;204a78d9-67aa-4e49-b285-bbb25c6ed142;204a78d9-67aa-4e49-b285-bbb25c6ed142;TCGA-AO-A1KQ-01A-21-A17I-20;;TCGA-AO-A1KQ-01;TCGA-AO-A1KQ-01A-11D-A13K-05;ccdaef5f-d816-426d-8e4f-b1bc561a11c5;TCGA-AO-A1KQ-01;;;;TCGA-AO-A1KQ-01;;;204a78d9-67aa-4e49-b285-bbb25c6ed142;;TCGA-AO-A1KQ-01A-11D-A13J-01;TCGA-AO-A1KQ-01;;204a78d9-67aa-4e49-b285-bbb25c6ed142;TCGA-AO-A1KQ-01A-11D-A13J-01;
TCGA-AQ-A54O-01;;;;;;;;;;;;;;;;;;;;;;;;;;;;;TCGA-AQ-A54O-01;;;;;;;;;;TCGA-AQ-A54O;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;51;Right Upper Outer Quadrant;Sentinel lymph node biopsy plus axillary dissection;;TCGA-AQ-A54O-F55731;TCGA-AQ-A54O;TCGA-AQ-A54O-01A;;Positive;;;;;Positive;Simple Mastectomy;;YES;;;-18694;617;;0;1001;;;;;;;90-99%;;;2014-1-14;MALE;;;;;1+;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;Fine needle aspiration biopsy;360;NO;Negative;;NO;14;Negative;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;NO;0;0;False;Yes;M0;N0;T2;Stage IIA;TCGA-AQ-A54O.B3884493-D0D2-445C-B9BB-BC475021EBA4.pdf;A54O;TUMOR FREE;;;;;;YES;YES;70-79%;;NO;Primary Tumor;1;;7th;;YES;NO;AQ;Breast;A;LIVING;2011;3c1b6647-26bb-4110-aaea-f542024e8bf3;3c1b6647-26bb-4110-aaea-f542024e8bf3;;;TCGA-AQ-A54O-01;TCGA-AQ-A54O-01A-11D-A268-05;e546ea71-dcab-49bf-b972-d6b6dbe57b8f;TCGA-AQ-A54O-01;TCGA-AQ-A54O-01A-11D-A25Q-09;;;TCGA-AQ-A54O-01;;;3c1b6647-26bb-4110-aaea-f542024e8bf3;;TCGA-AQ-A54O-01A-11D-A25N-01;TCGA-AQ-A54O-01;;3c1b6647-26bb-4110-aaea-f542024e8bf3;TCGA-AQ-A54O-01A-11D-A25N-01;
TCGA-AR-A1AV-01;Stage II;68;3;Stage IIB;1295;;Positive;MALE;Negative;4;5;4;Negative;M0;Positive;N1;1295;0;LumA;Luminal B;Positive;LumA/B;-2;-5;enrollment;T_Other;T2;LIVING;TCGA-AR-A1AV-01;High;C3-BRCA/Luminal;cluster 3;BRCA CIMP c7;BRCA nonbasal-like c8;BRCA nonbasal-like c7;miRNA c1uster 10;cluster 7;mutation cluster 4;TCGA-AR-A1AV;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;68;Left;Axillary lymph node dissection alone;;TCGA-AR-A1AV-F49475;TCGA-AR-A1AV;TCGA-AR-A1AV-01A;;Positive;;;;;Positive;Modified Radical Mastectomy;;;;;-24875;1233;;0;1864;;;;;;;70-79%;;Scheduled Follow-up Submission;2013-10-2;MALE;;;;;1+;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;Core needle biopsy;420;NO;Negative;;NO;25;Negative;;;;;;;;;;;;;;;;;;;;;3;7;;;;;;;;NO;1;;True;No;M0;N1;T2;Stage IIB;TCGA-AR-A1AV.5AD5B38F-5CC1-4A2F-96E6-F344D8FE0149.pdf;A1AV;TUMOR FREE;;;;;;YES;YES;70-79%;;YES;Primary Tumor;1;;6th;YES;NO;YES;AR;Breast;A;LIVING;2007;dddfaed8-0d0e-42ba-9add-fae3cc1e5a9a;dddfaed8-0d0e-42ba-9add-fae3cc1e5a9a;TCGA-AR-A1AV-01A-31-A13E-20;TCGA-AR-A1AV-01A-21D-A12Q-09;TCGA-AR-A1AV-01;TCGA-AR-A1AV-01A-21D-A12R-05;9432773f-696b-4104-9232-c6e6a6a379c2;TCGA-AR-A1AV-01;TCGA-AR-A1AV-01A-21D-A12Q-09;;TCGA-AR-A1AV-01;TCGA-AR-A1AV-01;TCGA-AR-A1AV-01A-21D-A12Q-09;;dddfaed8-0d0e-42ba-9add-fae3cc1e5a9a;;TCGA-AR-A1AV-01A-21D-A12N-01;TCGA-AR-A1AV-01;TCGA-AR-A1AV-01A-21R-A12P-07;dddfaed8-0d0e-42ba-9add-fae3cc1e5a9a;TCGA-AR-A1AV-01A-21D-A12N-01;TCGA-AR-A1AV-01
TCGA-BH-A0B2-01;Stage I;43;;Stage I;1242;;Positive;FEMALE;Negative;;;;Negative;M0;Negative;N0;1242;0;LumA;;Positive;;;;enrollment;T1;T1;LIVING;TCGA-BH-A0B2-01;;;;;BRCA nonbasal-like c8;;;;;TCGA-BH-A0B2;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;;;;;;;TCGA-BH-A0B2-01A;;;;;;;;;;;;;;1031;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;220;NO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;True;;;;;;TCGA-BH-A0B2.81FABA8A-1F6A-43DD-80F2-2466A7E8664E.pdf;;;;;;;;;;;;;Primary Tumor;1;;;;;;;;A;;;a27c5907-1ad2-4414-a9c9-448f1b484946;a27c5907-1ad2-4414-a9c9-448f1b484946;TCGA-BH-A0B2-01A-21-A13C-20;;;TCGA-BH-A0B2-01A-11D-A10N-05;2cdcaddf-2dd3-492b-a08f-71adc1065fec;;;;;;;TCGA-BH-A0B2-01;a27c5907-1ad2-4414-a9c9-448f1b484946;TCGA-BH-A0B2-01;TCGA-BH-A0B2-01A-11D-A10L-01;;TCGA-BH-A0B2-01A-11R-A10J-07;a27c5907-1ad2-4414-a9c9-448f1b484946;TCGA-BH-A0B2-01A-11D-A10L-01;
TCGA-BH-A0B2-11;;43;;;1242;;;FEMALE;;;;;;;;;1242;0;Normal;;;;;;enrollment;;;LIVING;TCGA-BH-A0B2-11;;;;;;;;;;TCGA-BH-A0B2;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;;;;;;;TCGA-BH-A0B2-11A;;;;;;;;;;;;;;1031;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;130;NO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;True;;;;;;;;;;;;;;;;;;;Solid Tissue Normal;11;;;;;;;;A;;;83b0bb89-66a7-4c70-87e1-78a0cc7de9e6;83b0bb89-66a7-4c70-87e1-78a0cc7de9e6;;;;TCGA-BH-A0B2-11A-11D-A10N-05;;;;;;;;;83b0bb89-66a7-4c70-87e1-78a0cc7de9e6;;;;TCGA-BH-A0B2-11A-11R-A10J-07;83b0bb89-66a7-4c70-87e1-78a0cc7de9e6;;
TCGA-BH-A0B4-01;Stage IIIA;65;5;No_Conversion;1191;;Positive;MALE;Positive;1;3;3;Negative;M0;Positive;N2;1191;0;LumA;Luminal A;Positive;ReacII;-3;-3;followup;T_Other;T2;LIVING;TCGA-BH-A0B4-01;High;C3-BRCA/Luminal;cluster 4;BRCA CIMP c7;BRCA nonbasal-like c8;BRCA nonbasal-like c7;miRNA cluster 4;cluster 6;mutation c1uster 9;TCGA-BH-A0B4;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;65;Left;Axillary lymph node dissection alone;;TCGA-BH-A0B4-F15435;TCGA-BH-A0B4;TCGA-BH-A0B4-01A;;Positive;;3+;;;Positive;Modified Radical Mastectomy;;NO;;;-23980;995;;0;1191;;;;;;;80-89%;2;Scheduled Follow-up Submission;2010-11-4;MALE;;;;;2+;40;5.65;2.83;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;3+;YES;;Core needle biopsy;340;NO;Equivocal;Positive;;10;Negative;;;;;;;;;;;;;;;;;;;;;4;6;;;;;;;;NO;6;;True;No;M0;N2;T2;Stage IIIA;TCGA-BH-A0B4.00C75246-4343-490D-9782-E6C0068C77B2.pdf;A0B4;TUMOR FREE;;;;;;;;50-59%;;YES;Primary Tumor;1;;;YES;NO;YES;BH;Breast;A;LIVING;2007;8af4a557-aebf-44ac-8ed5-b8b7b10ed24e;8af4a557-aebf-44ac-8ed5-b8b7b10ed24e;TCGA-BH-A0B4-01A-21-A13C-20;TCGA-BH-A0B4-01A-11W-A019-09;TCGA-BH-A0B4-01;;8406b2cf-e6f8-40ac-b0e9-f63535cc3574;TCGA-BH-A0B4-01;TCGA-BH-A0B4-01A-11W-A019-09;TCGA-BH-A0B4-01A-11D-A00Y-05;TCGA-BH-A0B4-01;;TCGA-BH-A0B4-01A-11W-A019-09;TCGA-BH-A0B4-01;8af4a557-aebf-44ac-8ed5-b8b7b10ed24e;TCGA-BH-A0B4-01;TCGA-BH-A0B4-01A-11D-A011-01;;TCGA-BH-A0B4-01A-11R-A00Z-07;8af4a557-aebf-44ac-8ed5-b8b7b10ed24e;TCGA-BH-A0B4-01A-11D-A011-01;TCGA-BH-A0B4-01
TCGA-BH-A0DD-01;Stage IIB;58;3;Stage IIB;1393;;Positive;MALE;Positive;1;3;4;Negative;M0;Positive;N1;1393;0;LumB;Luminal B;Positive;LumA/B;-6;-3;enrollment;T_Other;T2;LIVING;TCGA-BH-A0DD-01;High;C3-BRCA/Luminal;cluster 4;BRCA CIMP c7;BRCA nonbasal-like c8;BRCA nonbasal-like c7;miRNA cluster 4;cluster 4;mutation cluster 4;TCGA-BH-A0DD;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;58;Right;;;TCGA-BH-A0DD-F60386;TCGA-BH-A0DD;TCGA-BH-A0DD-01A;;Positive;;;;;Positive;Modified Radical Mastectomy;;;;;-21386;1248;;0;2486;;;;;NO;;;;;2014-6-9;MALE;;;;;;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;Core needle biopsy;430;NO;Positive;Positive;NO;22;Negative;;;;;;;;;;;;;;;;;;;;;4;4;;;;;;;;NO;0;;True;No;M0;N1a;T2;Stage IIB;TCGA-BH-A0DD.35FFF2A4-7956-47AC-B6B8-1AA6775E332B.pdf;A0DD;TUMOR FREE;;;;;;YES;YES;;;NO;Primary Tumor;1;;6th;;NO;YES;BH;Breast;A;LIVING;2006;e15ff180-38d3-4614-88ee-3645afaab54b;e15ff180-38d3-4614-88ee-3645afaab54b;TCGA-BH-A0DD-01A-21-A13B-20;TCGA-BH-A0DD-01A-31D-A12Q-09;TCGA-BH-A0DD-01;TCGA-BH-A0DD-01A-31D-A12R-05;7ac181c9-6dba-4e27-a5fc-09cf02f735cf;TCGA-BH-A0DD-01;TCGA-BH-A0DD-01A-31D-A12Q-09;;TCGA-BH-A0DD-01;TCGA-BH-A0DD-01;TCGA-BH-A0DD-01A-31D-A12Q-09;;e15ff180-38d3-4614-88ee-3645afaab54b;;TCGA-BH-A0DD-01A-31D-A12N-01;TCGA-BH-A0DD-01;TCGA-BH-A0DD-01A-31R-A12P-07;e15ff180-38d3-4614-88ee-3645afaab54b;TCGA-BH-A0DD-01A-31D-A12N-01;TCGA-BH-A0DD-01
TCGA-BH-A0DD-11;;58;;;1393;;;MALE;;;;;;;;;1393;0;LumA;;;;;;enrollment;;;LIVING;TCGA-BH-A0DD-11;;C3-BRCA/Luminal;;;;;;;mutation cluster 4;TCGA-BH-A0DD;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;58;Right;;;TCGA-BH-A0DD-F60386;TCGA-BH-A0DD;TCGA-BH-A0DD-11A;;Positive;;;;;Positive;Modified Radical Mastectomy;;;;;-21386;1248;;0;2486;;;;;NO;;;;;2014-6-9;MALE;;;;;;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;Core needle biopsy;460;NO;Positive;Positive;NO;22;Negative;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;NO;0;;True;No;M0;N1a;T2;Stage IIB;;A0DD;TUMOR FREE;;;;;;YES;YES;;;NO;Solid Tissue Normal;11;;6th;;NO;YES;BH;Breast;A;LIVING;2006;c38c7c6d-7c7c-45ea-9fae-a889e6ce0df5;c38c7c6d-7c7c-45ea-9fae-a889e6ce0df5;;;;;;;;;;;;;c38c7c6d-7c7c-45ea-9fae-a889e6ce0df5;;;;TCGA-BH-A0DD-11A-23R-A12P-07;c38c7c6d-7c7c-45ea-9fae-a889e6ce0df5;;
TCGA-D8-A1XS-01;Stage IIIC;48;3;Stage IIIC;18;;Positive;MALE;Positive;;;;Negative;M0;Positive;N3;18;0;LumB;;Positive;;;;enrollment;T_Other;T2;LIVING;TCGA-D8-A1XS-01;High;C3-BRCA/Luminal;cluster 2;BRCA non-CIMP c9;BRCA nonbasal-like c8;BRCA nonbasal-like c7;miRNA cluster 4;cluster 4;mutation cluster 4;TCGA-D8-A1XS;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;48;Left Upper Outer Quadrant;Axillary lymph node dissection alone;;TCGA-D8-A1XS-F12133;TCGA-D8-A1XS;TCGA-D8-A1XS-01A;;Positive;;;;;Positive;Modified Radical Mastectomy;;NO;;;-17708;164;;0;496;;;;;NO;% IHC;;;Scheduled Follow-up Submission;2012-3-19;MALE;;;;;3+;;;;;Other, specify;;No;;C50.9;8507/3;C50.9;;YES;;Core needle biopsy;340;NO;Positive;;;28;Negative;;;;;;;;;;;;;;;;;;;;;2;4;;;;;;;;NO;25;0;False;No;M0;N3a;T2;Stage IIIC;TCGA-D8-A1XS.6C97C157-05A0-45CE-91E9-3DC8946EFEDE.pdf;A1XS;TUMOR FREE;%IHC;;;>75%;>75%;;YES;;;YES;Primary Tumor;1;;7th;YES;YES;NO;D8;Breast;A;LIVING;2010;11b43261-66e4-4c28-8d24-6e38b4295f34;11b43261-66e4-4c28-8d24-6e38b4295f34;TCGA-D8-A1XS-01A-21-A17K-20;TCGA-D8-A1XS-01A-11D-A14K-09;TCGA-D8-A1XS-01;TCGA-D8-A1XS-01A-11D-A14N-05;22edabb4-30a0-4d5d-95f2-3ee9c3883fd1;TCGA-D8-A1XS-01;TCGA-D8-A1XS-01A-11D-A14K-09;;;TCGA-D8-A1XS-01;TCGA-D8-A1XS-01A-11D-A14K-09;;11b43261-66e4-4c28-8d24-6e38b4295f34;;TCGA-D8-A1XS-01A-11D-A14J-01;TCGA-D8-A1XS-01;;11b43261-66e4-4c28-8d24-6e38b4295f34;TCGA-D8-A1XS-01A-11D-A14J-01;
TCGA-E2-A14W-01;Stage IIA;78;5;Stage IIA;833;;Positive;FEMALE;Positive;3;3;4;Negative;M0;Negative;N0;833;0;LumB;Luminal B;Positive;Her2;0;-3;enrollment;T_Other;T2;LIVING;TCGA-E2-A14W-01;High;C3-BRCA/Luminal;cluster 2;BRCA non-CIMP c9;BRCA nonbasal-like c8;BRCA nonbasal-like c7;miRNA cluster 6;cluster 7;mutation cluster 12;TCGA-E2-A14W;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;78;Left Upper Outer Quadrant;Sentinel node biopsy alone;;TCGA-E2-A14W-F18803;TCGA-E2-A14W;;;Positive;3 Point Scale;;3 Point Scale;;Positive;Simple Mastectomy;;NO;;;-28664;;;0;974;;;;;NO;;;;Scheduled Follow-up Submission;2011-11-4;MALE;;;;;;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;Tumor resection;;;;Positive;;5;Negative;;;;;;;;;;;;;;;;;;;;;2;7;;;;;;;;NO;0;;;No;M0;N0;T2;Stage IIA;;A14W;TUMOR FREE;;;;;;;YES;;;NO;Primary Tumor;1;;6th;YES;NO;YES;E2;Breast;;LIVING;2008;f898f44d-a728-41cf-b1ac-20b1995a86b9;f898f44d-a728-41cf-b1ac-20b1995a86b9;TCGA-E2-A14W-01A-21-A13E-20;TCGA-E2-A14W-01A-11D-A12B-09;TCGA-E2-A14W-01;;de3f269f-cfa8-4ff2-bd60-14ffe2a45d83;TCGA-E2-A14W-01;TCGA-E2-A14W-01A-11D-A12B-09;TCGA-E2-A14W-01A-11D-A12E-05;TCGA-E2-A14W-01;TCGA-E2-A14W-01;TCGA-E2-A14W-01A-11D-A12B-09;;f898f44d-a728-41cf-b1ac-20b1995a86b9;;TCGA-E2-A14W-01A-11D-A12A-01;TCGA-E2-A14W-01;TCGA-E2-A14W-01A-11R-A12D-07;f898f44d-a728-41cf-b1ac-20b1995a86b9;TCGA-E2-A14W-01A-11D-A12A-01;TCGA-E2-A14W-01
TCGA-E2-A1IP-01;Stage IIB;42;;Stage IIB;427;;Positive;FEMALE;Negative;;;;Negative;M0;Positive;N1;427;0;Basal;;Negative;;;;enrollment;T_Other;T2;LIVING;TCGA-E2-A1IP-01;;;;;;;;;;TCGA-E2-A1IP;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;;;;;;;TCGA-E2-A1IP-01A;;;;;;;;;;;;;;359;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;80;NO;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;False;;;;;;TCGA-E2-A1IP.021D6868-16EA-4D55-9784-46A0F85C50C8.pdf;;;;;;;;;;;;;Primary Tumor;1;;;;;;;;A;;;dfd81aa5-5be4-4cf3-877f-0f52e01beb60;dfd81aa5-5be4-4cf3-877f-0f52e01beb60;;;;TCGA-E2-A1IP-01A-11D-A14H-05;;;;;;;;;dfd81aa5-5be4-4cf3-877f-0f52e01beb60;;;;;dfd81aa5-5be4-4cf3-877f-0f52e01beb60;;
TCGA-EW-A1PD-01;Stage IIA;61;5;Stage IIA;174;;Positive;MALE;Positive;;;;Negative;M0;Positive;N1;174;0;LumA;;Positive;;;;enrollment;T1;T1;LIVING;TCGA-EW-A1PD-01;High;C3-BRCA/Luminal;cluster 2;BRCA CIMP c7;KIRC-like c1;BRCA nonbasal-like c7;miRNA cluster 14;cluster 4;mutation c1uster 9;TCGA-EW-A1PD;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;61;Right;Sentinel lymph node biopsy plus axillary dissection;;TCGA-EW-A1PD-F29106;TCGA-EW-A1PD;TCGA-EW-A1PD-01A;;Positive;3 Point Scale;3+;3 Point Scale;;Positive;Modified Radical Mastectomy;;NO;;;-22536;112;;0;424;;;;;NO;;90-99%;;Scheduled Follow-up Submission;2012-3-8;MALE;;;20-29%;;2+;;>6;2.2;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;3+;YES;;Core needle biopsy;120;NO;Equivocal;Positive;;7;Negative;;;;;;;;;;;;;;;;;;;;;2;4;;;;;;;;NO;2;;True;No;M0;N1a;T1c;Stage IIA;TCGA-EW-A1PD.B6D80CA9-F4DA-4DFB-80BF-08BEE17142BD.pdf;A1PD;TUMOR FREE;;;;;;;YES;90-99%;;NO;Primary Tumor;1;;7th;YES;NO;YES;EW;Breast;A;LIVING;2010;69971d5c-5be4-4886-bf7c-753de9593a1e;69971d5c-5be4-4886-bf7c-753de9593a1e;TCGA-EW-A1PD-01A-21-A17J-20;TCGA-EW-A1PD-01A-11D-A142-09;TCGA-EW-A1PD-01;TCGA-EW-A1PD-01A-11D-A145-05;1dab2beb-b0c7-4eee-bc45-71997f6077e9;TCGA-EW-A1PD-01;TCGA-EW-A1PD-01A-11D-A142-09;;;TCGA-EW-A1PD-01;TCGA-EW-A1PD-01A-11D-A142-09;;69971d5c-5be4-4886-bf7c-753de9593a1e;;TCGA-EW-A1PD-01A-11D-A141-01;TCGA-EW-A1PD-01;;69971d5c-5be4-4886-bf7c-753de9593a1e;TCGA-EW-A1PD-01A-11D-A141-01;
TCGA-EW-A6SA-01;;;;;;;;;;;;;;;;;;;;;;;;;;;;;TCGA-EW-A6SA-01;;;;;;;;;;TCGA-EW-A6SA;TCGA Breast Cancer (BRCA);breast invasive carcinoma;Breast;;;;;59;Left|Left Lower Inner Quadrant;Sentinel node biopsy alone;;;TCGA-EW-A6SA;TCGA-EW-A6SA-01A;;Positive;;;;;Negative;Simple Mastectomy;;YES;;;-21623;152;;0;510;;;;;;;50-59%;;;2015-2-27;MALE;;;;;;;;;;Infiltrating Ductal Carcinoma;;No;;C50.9;8500/3;C50.9;;YES;;Core needle biopsy;80;NO;Negative;;;4;Negative;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;NO;;1;True;No;MX;N0 (i+);T2;Stage II;TCGA-EW-A6SA.9C971870-BA92-4E0C-9861-31C56B7E7D64.pdf;A6SA;TUMOR FREE;;;;;;YES;YES;;;NO;Primary Tumor;1;;7th;;YES;NO;EW;Breast;A;LIVING;2013;2aac1ce6-fc3e-474c-9e0e-5a6d05ff9168;2aac1ce6-fc3e-474c-9e0e-5a6d05ff9168;;;TCGA-EW-A6SA-01;TCGA-EW-A6SA-01A-21D-A32T-05;3C4C4A1F-544E-4CB5-A1E8-50534496B737;TCGA-EW-A6SA-01;;;;TCGA-EW-A6SA-01;;;2aac1ce6-fc3e-474c-9e0e-5a6d05ff9168;;TCGA-EW-A6SA-01A-21D-A32H-01;TCGA-EW-A6SA-01;;2aac1ce6-fc3e-474c-9e0e-5a6d05ff9168;TCGA-EW-A6SA-01A-21D-A32H-01;
